Today: 14 May 2026
Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act
11 May 2026
2 mins read

Pfizer Stock Faces a Fresh COVID Patent Overhang as Investors Wait for Its Next Growth Act

NEW YORK, May 10, 2026, 18:01 EDT

Acuitas Therapeutics has failed in its attempt to shield Pfizer Inc. and BioNTech’s Comirnaty COVID-19 vaccine from GSK’s patent claims, after a Delaware federal judge tossed the case. Judge Gregory Williams sided with GSK’s subsidiaries, dismissing the Acuitas action for lack of subject-matter jurisdiction. In effect, the court said it didn’t have the authority to hear the suit as filed, leaving the broader patent dispute over the high-profile vaccine unresolved.

The ruling stops short of saying if Comirnaty actually infringes on GSK’s patents. For Pfizer, that distinction is pressing: the company is working to steer investors’ attention away from its COVID lineup and onto potential growth in cancer, blood thinners, and obesity drugs, especially in the wake of a sharp sales reset during the pandemic.

With U.S. markets shut on Sunday, Pfizer ended Friday at $25.68, dropping 1.42% for a second session, despite the S&P 500 gaining 0.84%. Volume came in at 36.8 million shares, trailing its 50-day average.

On May 8, Pfizer’s $0.43 second-quarter dividend locked in its record date, with the payment coming June 12. The company notes this will be its 350th uninterrupted quarterly dividend—something income investors are watching closely as Pfizer works on restoring growth.

Pfizer posted first-quarter revenue of $14.5 billion last week, a 2% operational lift. Stripping out Comirnaty and Paxlovid, revenue climbed 7%. The drugmaker stuck to its 2026 outlook: $59.5 billion to $62.5 billion in revenue, with adjusted diluted earnings targeted between $2.80 and $3.00 per share.

Pfizer CEO Albert Bourla called it a “strong start” and highlighted obesity and oncology as key areas where he sees the company “positioned to lead.” CFO David Denton, noting “solid commercial performance,” said growth from both launched and acquired products reached 22% on an operational basis. Pfizer Investor Relations

Wall Street isn’t giving this quarter a free pass. J.P. Morgan’s Chris Schott pointed to some pipeline drugs that “could make the story more interesting over time.” Citi’s Geoff Meacham flagged new products as proof of “the commercial portfolio’s ability to offset ongoing COVID franchise declines.” RBC’s Trung Huynh was more direct: Pfizer is still “a catalyst story, not an earnings story.” Reuters

Pfizer is stepping into obesity treatments, vying with Eli Lilly, which already dominates the market with its blockbuster diabetes and weight-loss drugs. But Reuters says the first obesity drug Pfizer picked up in its Metsera deal, even if trial data go their way, won’t hit shelves before 2028.

Cancer is still the immediate focus. The U.S. Food and Drug Administration cleared Veppanu—Pfizer and Arvinas’ pill—this month for adults with advanced breast cancer who have an ESR1 mutation. “Patients needed a new modality, a new technology,” Arvinas CEO Randy Teel told Reuters. Reuters

Support is showing up in other parts of the portfolio. Eliquis, Pfizer’s blood thinner developed with Bristol Myers Squibb, brought in $2.17 billion in first-quarter revenue, according to Reuters. Padcev and Nurtec also contributed, giving a boost to the batch of freshly launched or recently acquired products.

The downside is still right there. Comirnaty sales slumped 59% to $232 million for the quarter, while Pfizer’s adjusted earnings per share dropped year over year. The Delaware legal dismissal leaves the big patent fight hanging unresolved. If trials in obesity or cancer don’t pan out, the company ends up relying even more on legacy drugs and trimming expenses.

Pfizer caught a break last month by settling patent fights with three generic manufacturers, pushing back rival versions of Vyndamax until 2031. That gives the heart drug a few more years before cheaper competition hits, offering some support for the company’s growth story beyond 2028. Still, it leaves the bigger question unresolved.

Stock Market Today

  • Teradyne (TER) Valuation Review Amid Strong Share Price Gains
    May 14, 2026, 6:56 AM EDT. Teradyne's shares closed at $363.38 after rallying 15.48% over 90 days, fueling investor interest. Analyst consensus values Teradyne at $369.53, implying modest upside of about 2%. Price targets vary widely from $270 to $470, reflecting mixed views on growth prospects. The stock trades at a price-to-earnings (P/E) ratio of 66.6, above the sector average, suggesting limited room for error if earnings disappoint. Key risks include tariffs and softness in robotics, possibly impacting margins and profits. Investors face a choice between paying a premium for expected growth or waiting for clearer signals. Market watchers should weigh recent gains against a stretched valuation before committing.

Latest articles

DXF Stock’s Big Move: Eason Technology Says No Hidden News Is Driving It

DXF Stock’s Big Move: Eason Technology Says No Hidden News Is Driving It

14 May 2026
Eason Technology said it had no undisclosed news after its NYSE American-listed ADR surged 29% to $0.76, with premarket quotes near $1.43. The company reported normal operations and compliance, following an exchange inquiry. Its 2025 annual filing showed a narrowed net loss of CNY8.04 million and a going-concern warning from its auditor. No new deals or sector moves were announced.
Fervo Energy Stock Pops 35% In Nasdaq Debut, Then Slips Before The Next Open

Fervo Energy Stock Pops 35% In Nasdaq Debut, Then Slips Before The Next Open

14 May 2026
Fervo Energy’s shares closed their Nasdaq debut at $36.54, up 35.3% from the $27 IPO price, before slipping to $35.55 in premarket trading. The Houston-based geothermal developer raised $1.89 billion by selling 70 million shares in an upsized offering. Fervo reports $7.2 billion in potential contracted revenue but remains unprofitable. Its first commercial facility is set to deliver power by late 2026.
Richtech Robotics Stock Jumps 10% Before Chicago Robot Demos as AI Service-Robot Bet Faces Test

Richtech Robotics Stock Jumps 10% Before Chicago Robot Demos as AI Service-Robot Bet Faces Test

14 May 2026
Richtech Robotics shares jumped 9.7% to $2.82 on Wednesday, with trading volume reaching 28.8 million ahead of live robot demonstrations at the National Restaurant Association Show in Chicago. The company reported an 8.8% drop in quarterly revenue to $1.147 million and a net loss of $8.4 million. Richtech remains small and unprofitable as it shifts focus to recurring revenue models.
Eos Energy Stock Gets a Cerberus Catalyst as Q1 Revenue Jumps 445%

Eos Energy Stock Gets a Cerberus Catalyst as Q1 Revenue Jumps 445%

14 May 2026
Eos Energy Enterprises reported a 445% jump in first-quarter revenue to $57 million and launched Frontier Power USA, a Cerberus-backed storage venture with a 2 GWh reservation. The company posted a $68 million adjusted EBITDA loss and a $44.4 million gross loss. Eos aims for positive adjusted EBITDA by year-end and expects its new Thorn Hill battery line to start production in June.
The Trade Desk Stock Drops After Weak Q2 Outlook: Why TTD Investors Are Worried Now
Previous Story

The Trade Desk Stock Drops After Weak Q2 Outlook: Why TTD Investors Are Worried Now

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

US Stock Market Today: Live Updates 11.05.2026

Go toTop